PHENYTOIN SODIUM INJECTION USP SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

PHENYTOIN SODIUM

Предлага се от:

HIKMA CANADA LIMITED

АТС код:

N03AB02

INN (Международно Name):

PHENYTOIN

дозиране:

50MG

Лекарствена форма:

SOLUTION

Композиция:

PHENYTOIN SODIUM 50MG

Начин на приложение:

INTRAMUSCULAR

Броя в опаковка:

2ML/5ML

Вид предписание :

Prescription

Терапевтична област:

HYDANTOINS

Каталог на резюме:

Active ingredient group (AIG) number: 0101375003; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2023-06-23

Данни за продукта

_ _
_Phenytoin Sodium Injection USP _
_Page 1 of 25_
PRESCRIBING INFORMATION
PR
PHENYTOIN SODIUM INJECTION USP
50 mg/mL
STERILE
ANTICONVULSANT AGENT
Hikma Canada Limited
Date of Preparation:
5995 Avebury Rd.
JUN 23, 2023
Mississauga, ON L5R 3P9
Control Number: 276186
_ _
_Phenytoin Sodium Injection USP _
_Page 2 of 25_
PR
PHENYTOIN SODIUM INJECTION USP
50 mg/mL
PART I: HEALTH PROFESSIONAL INFORMATION
THERAPEUTIC CLASSIFICATION
Anticonvulsant agent
INDICATIONS AND CLINICAL USE
•
Phenytoin Sodium Injection USP is an anticonvulsant used to control
tonic-clonic (grand mal)
and psychomotor or partial (focal) seizures.
•
Phenytoin Sodium Injection USP may be used for the prevention and
treatment of seizures
occurring during neurosurgery.
Phenytoin Sodium Injection USP should be used only when oral phenytoin
administration is not
possible.
CONTRAINDICATIONS
Phenytoin is contraindicated:
•
In patients with a history of hypersensitivity to phenytoin or to
other hydantoins.
•
In patients who have sinus bradycardia, sino-atrial block, second and
third degree AV block,
and Adams-Stokes syndrome.
•
In conjunction with delavirdine due to potential for loss of virologic
response and possible
resistance to delavirdine or to the class of non-nucleoside reverse
transcriptase inhibitors.
•
For intra-arterial administration in view of the high pH of the
preparation.
WARNINGS AND PRECAUTIONS
CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION
THE RATE OF INTRAVENOUS PHENYTOIN SODIUM INJECTION ADMINISTRATION
SHOULD NOT EXCEED 50 MG
PER MINUTE IN ADULTS AND 1-3 MG/KG/MIN (OR 50 MG PER MINUTE, WHICHEVER
IS SLOWER) IN
PEDIATRIC PATIENTS BECAUSE OF THE RISK OF SEVERE HYPOTENSION AND
CARDIAC ARRHYTHMIAS. IN
ELDERLY PATIENTS, THOSE WHO ARE GRAVELY ILL, OR THOSE WITH
CARDIOVASCULAR DISEASE, THE DRUG
SHOULD BE ADMINISTERED AT A RATE NOT EXCEEDING 25 MG/MINUTE, AND IF
NECESSARY, AT A SLOW RATE
OF 5 TO 10 MG/MINUTE. CAREFUL CARDIAC MONITORING IS NEEDED DURING AND
AFTER ADMINISTERING
INTRAVENOUS PHENYTOIN SODIUM INJECTION. ALTHOUGH TH